Top-News
Werbung
Attraktive Knock-Outs auf AbbVie Inc
Typ Hebel Bid / Ask WKN
Call
6,1 3,17 € / 3,19 €
FA8RG6
Typ Hebel Bid / Ask WKN
Put
3,7 5,20 € / 5,22 €
FD09L2
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf AbbVie Inc

AbbVie Aktie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
226,08 $
-2,63 $
-1,15%
194,16 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
353,90 Mrd. €
Streubesitz
25,26%
KGV
73,73
Dividende
1,64 $
Dividendenrendite
0,72%
neu: Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,63: JZ1WN5
Werbung

AbbVie News

29.06.25 - wallstreetONLINE Redaktion
Dividenden im Fokus: Fünf Dividenden-Favoriten für das zweite Halbjahr
Wegen geopolitischer Risiken bleiben solide Dividendenaktien weiter gefragt. Laut CNBC Pro bieten diese fünf Favoriten stabile Erträge, Analystenvertrauen und teils ein ...
22.06.25 - wallstreetONLINE Redaktion
Blockbuster-Kandidaten: 14 Aktien & 2 ETFs mit Milliardenpotenzial, die wie Bill Gates Alzheimer angehen
Viele forschende Pharmaunternehmen arbeiten intensiv an neuen Alzheimer-​Mitteln, die in den kommenden Jahren auf den Markt kommen könnten. Dies sind die ...
20.06.25 - PR Newswire
AbbVie Declares Quarterly Dividend
AbbVie Declares Quarterly Dividend PR Newswire
18.06.25 - PR Newswire
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-​to-Head Study Compared to ...
16.06.25 - PR Newswire
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-​Risk Myelodysplastic Syndromes PR Newswire
11.06.25 - PR Newswire
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus PR Newswire
03.06.25 - PR Newswire
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals PR Newswire
03.06.25 - PR Newswire
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference PR Newswire
30.05.25 - PR Newswire
AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" PR Newswire
30.05.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV PR Newswire
29.05.25 - PR Newswire
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
27.05.25 - PR Newswire
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio
AbbVie Features New Data Across Difficult-​to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio PR Newswire
22.05.25 - PR Newswire
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire
19.05.25 - PR Newswire
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV PR Newswire
16.05.25 - PR Newswire
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV PR Newswire
14.05.25 - PR Newswire
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-​tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression ...
14.05.25 - PR Newswire
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-​Generation siRNA Therapies Across Multiple Therapeutic Areas PR ...
13.05.25 - PR Newswire
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV
Investors who lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact Levi & Korsinsky about pending Class Action - ABBV PR Newswire
12.05.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders PR Newswire
09.05.25 - PR Newswire
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
Cerevel Therapeutics Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »